Nissim Darvish - 11 Mar 2022 Form 4 Insider Report for Chemomab Therapeutics Ltd. (CMMB)

Role
Director
Signature
/s/ Matthew Rudolph, Esq., Attorney-in-Fact for Nissim Darvish
Issuer symbol
CMMB
Transactions as of
11 Mar 2022
Net transactions value
+$5,136
Form type
4
Filing time
14 Mar 2022, 16:20:11 UTC
Previous filing
09 Mar 2022
Next filing
23 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CMMB American Depositary Shares Purchase $5,136 +1,200 $4.28 1,200 11 Mar 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMMB Option to Purchase American Depositary Shares Award $0 +6,820 $0.000000 6,820 07 Mar 2022 American Depositary Shares 6,820 $3.53 Direct F1, F3, F4
transaction CMMB Option to Purchase American Depositary Shares Award $0 +11,884 $0.000000 11,884 19 Apr 2021 American Depositary Shares 11,884 $27.26 Direct F1, F3, F5
transaction CMMB Option to Purchase American Depositary Shares Award $0 +10,123 $0.000000 10,123 16 Mar 2021 American Depositary Shares 10,123 $0.8000 Direct F1, F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
F2 The ADSs are held of record directly by the Ashdanit Medical Ltd. (the "IRA"), which is self-managed by the Reporting Person. The Reporting Person is the sole ultimate beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA.
F3 No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
F4 These options vest and become exercisable in their entirety on March 16, 2023, subject to the Reporting Person's continued service.
F5 These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
F6 The options reported in this row have all vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service.